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ABSTRACT  
Objective: The main purpose of this investigation was to prepare self-microemulsifying drug delivery system (SMEDDS) for enhancement of oral 
bioavailability of a poorly water soluble drug telmisartan (TLS), a BCS class II drug by improving its dissolution rate.  
Methods: Self-Emulsifying Drug Delivery Systems (SEDDS) of TLS were formulated using cinnamon essential oil as the oil phase, Gelucire 44/14 as 
the surfactant and Transcutol HP as co-surfactant. Drug-excipient interactions were studied by FTIR spectroscopy. The formulations were evaluated 
for its self-emulsifying ability, clarity, and stability of the aqueous dispersion after 48 h and the phase diagram was constructed to optimize the 
system. Selected formulations were characterized in terms of droplet size distribution, zeta potential, cloud point and were subjected to in vitro 
drug release studies. The bioavailability of optimized formulation was assessed in New Zealand white rabbits.  
Results: By considering smaller droplet size, higher zeta potential and faster rate of drug release the formulation TF9 was chosen as optimized 
SMEDDS formulations. TF9 was robust to different pH media and dilution volumes, remained stable after three cooling-heating cycles and after 
stored at 4 °C and 25 °C for 3 mo without showing a significant change in droplet size. The pharmacokinetic study in rabbits showed SMEDDS have 
significantly increased the Cmax and area under the curve (AUC) of TLS compared to suspension (P<0.05).  
Conclusion: SMEDDS can be an effective oral dosage form for enhancing aqueous solubility and improving oral bioavailability of poorly water 
soluble drugs. 
Keywords: Telmisartan, SMEDDS, Cinnamon essential oil, Gelucire 44/14, Transcutol HP, aqueous solubility, dissolution rate, bioavailability 




The oral route of drug administration has always been preferred due 
to its simplicity, patient convenience, compliance, accurate dosage 
and low cost of production [1]. A most essential requirement for oral 
absorption is that the drug must present in a solubilized state prior 
to passage across the gastrointestinal (GI) membrane. There are 
various pharmaceutical and physiological factors which affect the 
gastrointestinal absorption as well as the bioavailability of the drugs 
[2]. The reasons which contributed to poor oral bioavailability 
include less aqueous solubility, inadequate lipophilicity, and 
gastrointestinal degradation of the drug, presystemic metabolism 
and P-glycoprotein (Pgp) efflux of some drugs [3, 4]. Though 
continuous attempts are undertaken to minimize the solubility 
problems, approximately 40% of the currently marketed immediate-
release (IR) oral drugs [5] and up to 75% of compounds currently 
under development have been categorized to be poorly water 
soluble (<100 µg/ml) [6, 7]. These low soluble drugs exhibit poor 
bioavailability where dissolution is the rate-limiting step [8]. The 
various strategies such as solid dispersions [9], complexation with 
cyclodextrin [10], micronization, nanoparticles, permeation 
enhancers [11], cocrystal formation [12] and lipid-based 
formulations [13] have been reported in the literature. In recent years 
much attention has been focused on lipid-based formulations [14] 
with emphasis on self-emulsifying drug delivery systems (SEDDS) to 
improve oral bioavailability of lipophilic drugs [15]. Self-micro 
emulsifying drug delivery systems (SMEDDS) are defined as the 
isotropic mixtures of oil, surface active agents and co-surfactant (CoS) 
in which a particular drug is present in the dissolved state and such 
system rapidly form fine oil-in-water (o/w) microemulsions when 
introduced into the aqueous medium under mild agitation [16].  
Telmisartan, a BCS class II drug [17] is widely used in the treatment 
of hypertension. The drug is practically insoluble in water and shows 
dissolution rate limited bioavailability. Therefore the aim of present 
study was to improve the oral bioavailability of TLS via SMEDDS 
approach. 
The conventional SMEDDS include a relatively large amount of 
surfactants (>70%), which may induce GI irritation and side-effects 
[18]. In order to achieve a safe and efficient delivery system for the 
poor oral bioavailability drugs, the investigation was aimed to 
design a novel SMEDDS with a high proportion of cinnamon oil (an 
essential oil as the carrier for lipophilic drugs).  
The aim of the present investigation was to develop and characterize 
the optimized formulation of SMEDDS containing telmisartan and to 
assess its bioavailability in the rabbits.  
In the present investigation, essential oil was used to replace part of 
the surfactant for reducing the potential toxicity of the formulation. 
It was observed that high essential oil containing SMEDDS 
formulations possess excellent self-emulsifying property, stability 
and suitable in vitro drug release profile, without affecting the drug 
loading capacity. 
Studies on mean particle sizes of microemulsions were conducted by 
dynamic light scattering (DLS) technique. The in vitro release 
profiles of telmisartan from SMEDDS and the prepared TLS 
suspension were compared. Various pharmacokinetics parameters 
were investigated for optimized SMEDDS and prepared TLS 
suspension and relative oral bioavailability of TLS was assessed. 
MATERIALS AND METHODS 
Materials 
Telmisartan was received as a gift sample from Dr. Reddy’s 
Laboratory (Hyderabad, India). Gelucire 44/14 (Lauroyl Polyoxyl-32 
glycerides) and Transcutol HP (Diethylene glycol monoethyl ether) 
were kindly provided by Gattefosse India Pvt. Ltd. (Mumbai). Anise 
oil, cinnamon oil, and lemon essential oil were purchased from 
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Genuine Chemicals Co. (Mumbai, India). Oleic acid ((9Z)-Octadec-9-
enoic acid), polyethylene glycol 400 and propylene glycol were 
purchased from Molychem (Mumbai, India). Tween (R) 80 
(Polyoxyethylene (20) sorbitan monooleate) and olive oil were 
purchased from Loba Chemie Pvt. Ltd. (Mumbai, India). Glycerol was 
purchased from Sisco Research Laboratory (Mumbai, India), 
Cremophore RH40 and dialysis membrane (DM-50) were purchased 
from Himedia (Mumbai, India). All the excipients and reagents were 
of analytical grade and double distilled water was freshly prepared 
whenever required throughout the study. For the pharmacokinetic 
study, New Zealand white rabbits were obtained from Sanzyme 




Solubility studies for the drug in different vehicles were carried by 
placing an excess amount of telmisartan in screw-capped vials 
containing 2 ml of vehicle. To facilitate the solubilization, the 
suspensions were heated on a water bath at 40 °C and then stirred 
using vortex mixer. The suspensions were continuously agitated on a 
water bath shaker for 48 h at ambient temperature until equilibrium 
was reached. Then the samples were centrifuged at 3000 rpm for 15 
min and the supernatant was taken, filtered through the membrane 
filter (0.45 µm, 13 mm, Whatman, USA). The filtrates were suitably 
diluted with methanol and analyzed by UV-Visible spectrophotometer 
(Shimadzu, Japan) for the dissolved drug at 294 nm [19]. 
Surfactant and oil miscibility 
The oil and surfactant in the ratio of 1:1 were shaken at 40 °C in 5 ml 
transparent glass vials. The miscibility was monitored optically and 
considered to be good when the mixture was transparent. 
Fourier transform infrared spectroscopy  
To investigate any possible interaction between the drug and 
utilized excipients, FTIR spectroscopy was used [20]. The IR spectra 
of pure drug and that of SEDDS were recorded by using FTIR 
Spectrometer (FTIR-8400S, Shimadzu, Japan). Sample preparation 
includes mixing a small quantity of the sample with Nujol and was 
placed in the FTIR sample holder. The IR spectrum was recorded 
from regions of 4000 cm-1 to 400 cm-1. 
Preparation of SEDDS 
A series of SEDDS formulations were prepared with varying ratios of 
oil (30–70%), surfactant (20–69%) and co-surfactant (4–27%) as 
shown in table 1. The surfactant and co-surfactant (S/CoS) were 
used at the ratio of 2:1, 4:1 and 6:1. A single dose of TLS (20 mg/ml) 
was incorporated in all formulations. The formulations were 
developed by dissolving the drug in oil followed by addition of 
surfactant previously heated to 50 °C and co-surfactant in glass vials. 
The resultant mixtures were stirred continuously by vortex mixing 
and heated at 50 °C to obtain a homogeneous isotropic mixture. The 
SEDDS formulations were stored at ambient temperature until 
further use. 
 
Table 1: Composition of SEDDS formulations of telmisartan (% v/v) 
Formulation Ingredients (% v/v) 
Cinnamon oil Gelucire 44/14 Transcutol HP 
TF1 20 53.3 26.6 
TF2 20 64 16 
TF3 20 68.5 11.4 
TF4 30 46.6 23.3 
TF5 30 56 14 
TF6 30 60 10 
TF7 40 40 20 
TF8  40 48 12 
TF9 40 51.4 8.5 
TF10 50 33.3 16.6 
TF11 50 40 10 
TF12  50 42.6 7.4 
TF13 60 26.6 13.4 
TF14 60 32 8 
TF15 60 34.3 5.7 
TF16 70 20 10 
TF17 70 24 6 
TF18 70 25.7 4.3 
 
Construction of ternary phase diagrams 
Ternary phase diagrams of the selected oils, surfactants and co-
surfactants at various proportions were constructed to identify the 
self-emulsification regions. All the formulations were investigated 
with various proportions of oil, surfactant and co-surfactant for each 
system. All the formulations were observed visually immediately for 
spontaneity of emulsification, clarity, phase separation and 
precipitation of drug and excipients [21]. Briefly, 0.5 ml formulations 
were added drop by drop to 500 ml enzyme-free simulated gastric 
fluid (SGF pH 1.2) at 37.0±0.5 °C; the mixtures were gently stirred on 
a magnetic stirrer at 100 rpm to simulate the gastrointestinal 
wriggle. The resultant emulsions were stored for 48 h at ambient 
temperature and observed for clarity, coalescence of droplets, phase 
separation and drug precipitation. Emulsions showing phase 
separation, cracking and coalescence of oil droplets were judged as 
unstable emulsions. All the studies were repeated three times with 
and without drug with similar observations made between repeats. 
The mixtures were considered well dispersed when the formulation 
spread quickly in SGF and was clear or milk-white color with no 
phase separation or coalescence after the stirring stopped. Phase 
diagram was constructed identifying the self-emulsifying region 
using ProSim Ternary Diagram software. 
Characterization of SEDDS 
Visual assessment of self-emulsification time and appearance 
Assessment of the self-emulsifying properties of SEDDS formulations 
was performed by visual observation. The USP type II dissolution 
apparatus (Electrolab, Mumbai, India) was used to assess the efficiency 
of self-emulsification of different formulations. 1g of each formulation 
was added dropwise into 500 ml of distilled water maintained at 37 °C 
with gentle agitation condition provided by rotating paddle at 50 rpm. 
Begin timing after the formulation was added completely and stop until 
the homogeneous emulsion was formulated. The appearance of 
emulsions was monitored and categorized as clear, translucent and 
cloudy. The in vitro performances of the formulations were visually 
assessed using the grading system as discussed by Khoo et al. [22]. 
Droplet size and zeta (ζ)–potential measurements 
The mean droplet size (z average), polydispersity index (PDI) and ζ-
potential of stable formulations were determined at 25 °C with a 
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Zetasizer Nano-ZS dynamic light scattering apparatus (Malvern 
Instruments, UK). Each formulation was diluted with filtered (0.45 
μm, Millipore) double distilled water before analysis. Size analysis 
was carried at 25 °C with an angle of detection of 90 °. 
Effect of pH and robustness to dilution 
Formulations were subjected to 50, 100, 1000 and 3000 fold dilution 
with enzyme-free SGF (pH 1.2), enzyme-free simulated intestinal 
fluid (SIF, pH 6.8) and distilled water. The resultant diluted 
emulsions were observed for any physical changes such as 
(coalescence of droplets, phase separation or precipitation of drugs) 
after 24 h storage [23]. 
Formulation stability 
Selected TLS-loaded formulations underwent three consecutive 
cooling and heating cycle to assess their stability [24]. Each cycle 
consisted of cooling the formulation at 4 °C for 24 h in the 
refrigerator, followed by heating at 45 °C for 48 h in an incubator. 
The droplet size, PDI, and ζ-potential of the emulsions were 
determined after each cycle, and moreover every month on 
formulations stored at 4 °C and 25 °C for up to three months. 
Cloud point measurement 
The cloud point measurement was carried out for the stable 
formulations. The formulation was diluted 100 times with distilled 
water and kept in a water bath which was maintained at a 
temperature of 25 °C with a gradual increase of temperature at a 
rate of 5 °C/min and the corresponding cloud point temperatures 
were read at first sign of turbidity by visual observation [25]. 
In vitro drug release studies 
Drug release experiments were conducted using a modified dialysis 
method [26]. Initially, the dialysis membrane tubing was soaked in 
the release medium for 12 h at room temperature which was treated 
at 40 °C before the start of the experiment. The diluted SMEDDS 
formulation (equivalent to 20 mg TLS) and 1 ml TLS suspension (20 
mg TLS in SGF pH 1.2 as the control) were placed in dialysis tubing 
and clamped on both sides. The secured dialysis tube was tied to the 
paddle of the apparatus and allowed to rotate freely in the 
dissolution vessel of USP type-II dissolution apparatus (Electrolab 
Dissolution Tester (USP) TDT-06L, Mumbai, India) containing 500 
ml of enzyme-free SGF (pH 1.2) at 37±0.5 °C and stirred at 50 rpm. 
An aliquot of 5 ml was withdrawn at predetermined time intervals 
(15, 30, 45, 60, 75, 90, 120, 150 180 and 240 min) and filtered 
through 0.45 μ filter. The withdrawn volume was replenished 
immediately with the same volume of fresh medium in order to keep 
total volume constant and maintain sink conditions. The 
concentration of TLS in the filtrate was analyzed using UV 
spectrophotometer at 294 nm. The blank SEDDS without drug was 
carried out similarly and used as a reference to circumvent 
interference from the formulation components if any. The mean of at 
least three determinations was used to calculate the drug release. 
Pharmacokinetic studies  
In vivo studies were carried out as per the guidelines of the 
Institutional Animal Ethics Committee (Regd. No. IAEC/GIP-
1287/SKS-F/Approved/10/2017-18). New Zealand white rabbits 
(1.8–2.0 kg) of either sex were housed under standard conditions of 
temperature, relative humidity, and light. Unless otherwise 
specified, food and water were given ad libitum. 
All animals were separated into two groups [Group-I and Group-II], 
with 6 animals in each group and fasted for 24 h. The TLS (1 mg/kg) 
pure drug in aqueous suspension in 0.5% sodium carboxymethyl 
cellulose for Group-I animals and optimized SMEDDS formulation 
(equivalent to 1 mg/kg TLS) for Group-II animals were administered 
orally with the help of oral feeding needle. Water was given ad 
libitum during fasting and throughout the experiment. 
After drug administration, 1 ml of blood sample was collected from 
marginal ear vein at time intervals of 0, 0.5, 1, 1.5, 2, 3, 4 and 6 h in 
the precoated EDTA tubes. The samples were centrifuged at 3000 
rpm for 15 min and the separated plasma samples were stored at 
refrigerated conditions (2–8 °C) until analysis. Telmisartan contents 
of the plasma samples were determined by HPLC method. 
Estimation of pharmacokinetic parameters 
The pharmacokinetic parameters for the drug in control and 
optimized SEDD formulation following oral administration were 
determined from plasma concentration data. Various pharmacokinetic 
parameters such as peak plasma concentration (Cmax), time of peak 
plasma concentration (tmax), the area under the curve (AUC) were 
calculated in each case using the data. The total area under the 
concentration-time curve (AUC) from time zero to 8 h were be 
calculated by the trapezoidal rule method. The maximal concentration 
(Cmax) and the time to maximal concentration (tmax) were obtained 
directly by observation. The relative bioavailability (BA) of SMEDDS 








The pharmacokinetic parameters were performed by non-
compartmental analysis. All values are expressed as the mean±SD 
Statistical treatment of the data 
The pharmacokinetic data of TF9 SMEDDS and reference 
formulations were compared by the Student’s t-test. A p-value of less 
than 0.05 was considered as statistically significant. 
RESULTS  
Solubility studies 
The drug-loading capacity of the SEDDS formulations depends on 
the solubility of TLS in the various vehicles of the system, which was 
determined by solubility studies. The results are presented in fig. 1. 
 
 
Fig. 1: Solubility of telmisartan in various vehicles; each value is expressed as mean±SD (n = 3) 
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Fig. 2: FTIR spectrum of telmisartan 
 
 
Fig. 3: FTIR spectrum of SEDDS (TF9) 
 
Ternary phase diagram 
A ternary phase diagram was investigated for the prepared 
formulations. Before the construction of ternary phase diagrams, the 
miscibility between surfactants and oils was investigated to select 
the best components. The mixture of surfactant Gelucire 44/14 and 
cinnamon essential oil resulted in clear solutions. Formation of 
emulsion systems (the green area in fig. 4) was observed at ambient 
temperature. 
Self-emulsification efficiency and appearance 
The efficiency of self-emulsification could be estimated by 
determining the rate of emulsification. The results of rate of 
emulsification are shown in table 2. The results suggested that all 
the formulations except TF7 and TF8, up to 40% oil content showed 
the emulsification time of less than 60 sec.  
Droplet size and zeta (ζ) potential 
Droplet size, PDI and ζ-potential of the optimized SEDDS in SGF with 
(20 mg/ml) and without TLS are listed in table 3. 
 
Fig. 4: Ternary phase diagram of SEDDS between cinnamon oil, 
gelucire 44/14 and transcutol HP (green domain indicates the 
region of self emulsification
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Table 2: Evaluation parameters of telmisartan loaded SEDDS formulations 
Formulation  Self-emulsification time* [Sec] Clarity* Stability after 48 h* Visual grading* 
TF1 32±3 Translucent Unstable B 
TF2 24±1 Transparent Stable A 
TF3 21±2 Transparent Stable A 
TF4 42±4 Translucent Unstable C 
TF5 34±2 Translucent Stable B 
TF6 30±3 Transparent Stable A 
TF7 103±4 Cloudy Unstable C 
TF8 82±3 Translucent Stable B 
TF9 54±2 Translucent Stable B 
TF10 142±4 Cloudy Unstable D 
TF11 119±3 Cloudy Unstable C 
TF12 112±2 Translucent Unstable C 
TF13 171±4 Cloudy Unstable D 
TF14 138±4 Cloudy Unstable D 
TF15 125±3 Cloudy Unstable C 
TF16 208±4 Cloudy Unstable D 
TF17 184±6 Cloudy Unstable D 
TF18 162±5 Cloudy Unstable D 
 *Data expressed as mean±SD (n=3) 
 
Table 3: Droplet size, PDI and ζ-potential of optimized SMEDDS in 500 ml SGF (pH 1.2) at room temperature, with and without drug 
Formulation  Without drug With drug (20 mg/ml) 
Droplet size* [nm] PDI Zeta potential* [mV] Droplet size* [nm] PDI Zeta potential* [mV] 
TF2 201.98±9.24 0.192 -7.39±2.61 236.58±10.37 0.205 -7.53±2.91 
TF3 187.65±8.18 0.201 -7.25±2.86 205.26±9.61 0.227 -7.59±2.72 
TF5 198.54±6.77 0.192 -5.53±2.29 213.82±5.96 0.186 -6.04±2.15 
TF6 135.52±7.31 0.283 -8.26±2.41 161.14±8.48 0.276 -8.37±2.84 
TF8 179.37±9.46 0.289 -7.01±2.35 197.65±7.29 0.315 -6.57±2.38 
TF9 134.85±3.55 0.275 -4.52±0.72 150.72±3.64 0.290 -4.58±0.96 
TF12 262.46±7.39 0.316 -4. 95±1.52 278.37±6.18 0.328 -5.75±1.43 
 *Data expressed as mean±SD (n=3)  
 
 
Fig. 5: Droplet size distribution of telmisartan-loaded microemulsion (TF9) 
 
Sahoo et al. 
Int J App Pharm, Vol 10, Issue 4, 2018, 117-126 
122 
 
Fig. 6: Zeta potential of telmisartan-loaded microemulsion (TF9) 
 
Effect of pH and robustness to dilution 
 
Fig. 7: Particle size distributions of the micro emulsions generated from Formulation TF9 in (A): enzyme free simulated gastric fluid (pH 
1.2), (B): enzyme free simulated intestinal fluid (pH 6.8) and (C): distilled water 
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Table 4: Effects of cooling and heating cycles on the dynamic characteristics of micro emulsions obtained from TF9 containing 20 mg/ml 
Telmisartan in enzyme free SGF (pH 1.2, 500 ml) 
Cooling (4 °C) and heating (45 °C) cycle Droplet size* [nm] PDI Zeta potential* [mV] 
-- 150.72±3.64 0.290 -4.82±0.96 
First 154.68±2.85 0.293 -4.81±0.85 
Second 155.29±4.38 0.305 -4.79±0.99 
Third 157.16±3.47 0.287 -4.83±0.91 
 *Data expressed as mean±SD (n=3)  
 
Table 5: Effects of storage conditions on the dynamic characteristics of microemulsion obtained from TF9 containing 20 mg/ml 
Telmisartan in enzyme free SGF (pH 1.2, 500 ml) 
Storage Time 
(months) 
Temperature, 4 °C Temperature, 25 °C 
Droplet size* [nm] PDI Droplet size* [nm] PDI 
1 150.36±5.86 0.214 151.45±4.39 0.383 
2 150.87±6.69 0.371 152.92±7.72 0.412 
3 151.12±5.25 0.358 153.36±7.45 0.425 
 *Data expressed as mean±SD (n=3)  
 
Formulation stability 
The stability of TF9, after three cooling and heating cycles, is 
summarized in table 4 and the effect of storage conditions on the 
microemulsion stability is presented in table 5. 
Cloud point measurement 
The cloud point is the temperature above which the clarity of 
formulation turns to cloudiness. This is due to drug precipitation 
and phase separation of the emulsion. Since both the drug 
solubilization and stability of emulsion decreases with phase 
separation, cloud point should be preferably above 37 °C.  
The cloud point temperatures of different formulations determined 
were in the range of 62–76 °C. 
In vitro drug release study 
To facilitate the real drug release pattern the dialysis bag method 
was utilized in drug release studies and the drug release pattern of 
SMEDDS shown in fig. 8. 
 
 
Fig. 8: In vitro release profile of Telmisartan suspension and Telmisartan-SMEDDS (Emulsified with SGF, pH = 1.2, 10 ml) in SGF (pH = 1.2, 
500 ml). Data expressed as mean±SD (n=6) 
 
 
Fig. 9: Plasma concentration of telmisartan after oral administration of TLS suspension and SMEDDS (TF9) to rabbits. Data expressed as 
mean±SD (n=6) 
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Table 6: Pharmacokinetic parameters of Telmisartan after oral administration of TLS suspension and SMEDDS (TF9) in rabbits 
Parameters* TLS suspension SMEDDS 
Cmax (µg/ml) 81.62±5.99 145.28±7.34 
tmax (h) 3.00±0.00 2.00±0.00 
AUC(0-8)h (µg h/ml) 425.48±11.35 1013.21±15.42 
Relative bioavailability (%) -- 238.15 
 Each value expressed as mean±SD (n = 6)., *P<0.05 by the Student t-test. 
 
Pharmacokinetic studies 
The plasma concentration versus time profiles of TLS in rabbits for 
SMEDDS and TLS suspension following oral administration are 
presented in fig. 9. The pharmacokinetic parameters of TLS were 
computed and tabulated in table 6. 
DISCUSSION 
Among the five oils those have been tested, TLS is highly soluble in 
cinnamon essential oil (about 138.09±2.82 mg/ml) which is better 
than anise oil (47.92±1.32 mg/ml), lemon essential oil (34±2.66 
mg/ml), olive oil (20.59±1.09 mg/ml) and oleic acid (16.78±1.78 
mg/ml). The surfactant has a pivotal role in stabilizing 
microemulsions, its nature and amount determining droplet size and 
stability [27]. Nonionic surfactants are usually preferred because of 
their lower toxicity and higher stability to the effect of pH and ionic 
strength than ionic and amphiphilic surfactants [28]. The 
hydrophilic-lipophilic balance (HLB) is a measure of the degree to 
which a substance is hydrophilic or lipophilic [29]. An HLB value of 
20 defines a fully hydrophilic molecule, while a value of 0 defines a 
lipophilic one [30]. The stability of emulsions depends also on the 
ratio between the high HLB and low HLB surfactant amounts 
[21,31]. As shown in fig. 1, among all the investigated surfactants, 
TLS exhibited quite higher solubility in Gelucire 44/14 (HLB 14) 
76.02±2.79 mg/ml than Cremophor RH40 (HLB 15), 38.5±1.45 
mg/ml; Tween 80 (HLB 15), 9.75±1.68 mg/ml; and the former was 
selected for further investigations. The solubility of telmisartan in 
different co-surfactants was investigated and a higher solubility was 
found in Transcutol HP (48.53±2.75 mg/ml) than propylene glycol 
(8.03±1.45 mg/ml), polyethylene glycol 400 (5.32±1.04 mg/ml) and 
glycerol (5.79±1.72 mg/ml). So Transcutol HP was selected as co-
surfactant which helps in further lowering of interfacial tension. 
Based on the solubility results the SEDDS formulations were 
developed employing varying concentrations of cinnamon oil (20–
70%), Gelucire 44/14 (20–69%), and Transcutol HP (4–27%). 
FTIR spectra of telmisartan (fig. 2) showed characteristic peaks of 
aliphatic C-H stretching at 2958 cm-1, C=O stretching at 1697 cm-1, C-
N stretching at 1126 cm-1, C=N stretching at 1600 cm-1. The FTIR 
spectra of SEDDS (fig. 3) also showed all these characteristic peaks 
with minor shifts. These results from FTIR spectral analysis 
indicated that there was no chemical interaction between drug and 
excipients used in the formulation. 
Ternary phase behavior investigations help to choose the proper 
concentration of excipients i.e. oil proportion and optimum S/CoS 
ratio in the formulation to produce emulsions with good stability 
[32]. As a fact, all surfactants are potentially irritant or are poorly 
tolerated [33], so large amounts of surfactants may cause irritation 
in the gastrointestinal tract [34]; systems which contain a higher 
proportion of essential oil should be preferred. Since the free energy 
required to form an emulsion is very low, due to the surfactant 
which reduces the interfacial tension, the formation is 
thermodynamically spontaneous. Surfactants also provide a 
mechanical barrier to coalescence [35]. After observing clarity, 
stability after 48 h, it was noted that all formulations with S/CoS 
ratio of 6:1 except TF15 and TF18 i.e. TF3, TF6, TF9 and TF12 
produced stable emulsions, whereas the resultant emulsions of 
formulations with S/CoS ratio of 2:1 showed phase separation and 
precipitation (results are shown in table 2). Among the S/CoS ratio 
of 4:1, formulations TF2, TF5, and TF8 also produced stable 
emulsions. The reason for this may be due to the water solubility of 
Transcutol HP and its tendency to redistribute between aqueous 
phase and emulsion–water interface, leading to loss of solvent 
capacity resulting in an unstable emulsion.  
However, with an increase of oil proportion over 40% to 70%, the 
emulsification time was increased up to more than 200 sec. These 
visual observations indicated that higher the proportion of 
surfactant system, greater the spontaneity of emulsification. This 
may be due to excessive penetration of aqueous phase into the oil 
phase causing very large interfacial disruption and expulsion of 
droplets into the bulk aqueous phase [36]. SEDDS that passed this 
test in grades A and B were selected for further evaluation, as grades 
A and B formulations will remain as SNEDDS or SMEDDS when 
dispersed in G. I. fluids. All other SEDDS that were falling in grades C, 
D and E were discarded for further evaluation. 
In agreement with P. Patil et al. (2007) [37], a slight increase in 
droplet size was observed for the TLS-loaded SEDDS. This can be 
attributed to the preferential dissolution of the drug in the 
interfacial film (formed by the surfactant and co-surfactant) that 
increases the interfacial tension. Moreover, the addition of the drug 
could induce surfactant aggregation, thus reducing its efficiency. The 
PDI values were below 0.5 indicated that the droplets were uniform 
in size. The ζ-potential is correlated to the electrostatic repulsion 
and aggregation of the droplets. High positive or negative ζ-potential 
values (higher electrostatic repulsive forces) arrest coalescence, 
thus enabling stability of the emulsions [38-40]. The negative 
charges were due to the presence of free fatty acids in the surfactant 
[19, 28]. The droplet sizes of all the optimized formulations except 
TF12 were below 250 nm suggested SMEDD formulations. Again 
among SMEDDS, the formulation TF9 incorporate high proportions 
of oil as compared to conventional SMEDD formulations where the 
later is prepared by incorporating a large amount of surfactant or 
surfactant-cosurfactant mixture (>70%). The droplet size of TF9 
with telmisartan was found to be 150.72±3.64 nm (fig. 5) with PDI of 
0.290. The zeta potential of the emulsion developed by TF9 was 
found to be -4.58±0.96 mV (fig. 6). The conductivity of the emulsion 
was 0.200 mS/cm, which means the emulsion was fine oil in water 
(conductivity>10 μS/cm) [27]. 
The stable SMEDDS formulations exposed to different pH media 
such as enzyme-free SGF (pH 1.2), enzyme-free SIF (pH 6.8) and 
distilled water to mimic the in vivo conditions revealed no 
precipitation or phase separation indicating all the formulations 
were found to be robust towards different pH conditions (fig. 7). 
However, the formulations were robust over the wider degree of 
dilution without any signs of drug precipitation and phase 
separation. 
The droplet size increased with no significant changes of the ζ-
potential after three cooling and heating cycles. Moreover, the 
formulation didn’t exhibit any drug precipitation or phase 
separation during the whole process. No marked difference of 
droplet size was observed for formulations stored at 4 °C or 25 °C 
(table 5). The above findings indicated that this telmisartan loaded 
formulation is thermodynamically stable. 
The reason for higher cloud point temperature may be attributed to 
the solubility of the drug in oil and surfactant system, the optimized 
ratio of S/CoS and/or surfactants with higher HLB values. This infers 
good thermal stability of all the tested formulations. Above 76 °C, 
phase separation and precipitation was observed, this is due to 
dehydration of surfactant mixture [23]. 
The drug release from SMEDDS was significantly greater than that of 
the telmisartan suspension. In 2 h, the SMEDDS TF6, TF8, TF9 and 
TF12 released more than 80% of the drug in comparison to 31.5% of 
the telmisartan from suspension. The formulations TF9 and TF12 
released almost all drug (>95%) in compared to other SMEDDS, with 
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just a small difference among the different SMEDDS that are 
consistent with the droplet sizes. In addition, the release from 
SMEDDS was faster, further supporting the hypothesis that micro-
scale emulsions can improve the release of lipophilic drugs. The drug 
release pattern of SMEDDS reveals that the highest drug release was 
observed with TF9 formulation after 60 min. that could be due to 
proper compromise between proportions of oil and surfactant in the 
system. Though the formulations TF2, TF3 and TF6 produced 
emulsions with better spontaneity and more clarity, these 
formulations showed 36.29±3.91%, 41.61±2.17% and 59.26±2.62% 
drug release respectively, this may be due to high surfactant 
proportion in the formulation. However, the high surfactant 
proportion is usually concomitant with a higher probability of 
surfactant migration into surrounding aqueous media upon 
dispersion which is supposed to form micelles that trap free drug 
inside, with subsequent hindrance in drug release [33]. The drug 
release pattern from TF9 formulation followed first order up to 1 h. 
Results of the pharmacokinetic study showed that the Cmax and 
AUC(0–8 h) of TLS in SMEDDS increased by 1.78-fold and 2.38 fold 
respectively compared to the TLS suspension. Additionally, the TLS 
in SMEDDS was absorbed more rapidly and reached its peak 
concentration faster (p<0.05). The absorption of telmisartan from 
SMEDDS resulted in a 2.4-fold increase in bioavailability compared 
with the suspension formulation. 
CONCLUSION 
In the present study, a novel SMEDDS was successfully designed as a 
stable, high essential oil ratio (40%) and high drug-loaded 
(approximate 20%) formulation for the solubility and dissolution 
rate enhancement of practically water insoluble drug, telmisartan. 
The formulation composition and pH of the emulsifying medium 
significantly impacted the droplet size. The stability study confirmed 
that the SMEDDS formulations could withstand various storage 
conditions with excellent stability. The in vitro drug release study 
demonstrated that the release from SMEDDS was more efficient 
when compared with the drug suspension. Also in vivo studies for 
clinical purpose, SMEDDS showed significantly greater extent of 
absorption than the suspension formulation. The relative 
bioavailability of SMEDDS to the suspension formulation (20 mg/ml) 
was 238%. Under these circumstances, the present SMEDDS would 
be a promising novel system to improve the aqueous solubility of 
poorly soluble drug and potentially the bioavailability. 
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